JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Trump Says Anthropic No Longer Seen as National Security Threat 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
SAN RAMON, Calif., Feb. 02, 2016 -- SteadyMed Ltd. (Nasdaq:STDY), a pre-NDA stage specialty pharmaceutical company focused on the development of drug products to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan Rigby, President and Chief Executive Officer will present at the BIO CEO conference on Tuesday, February 9, 2016. Mr. Rigby will provide an overview of the company’s business including its lead drug product candidate Trevyent; a combination of the company’s PatchPump and treprostinil for the treatment of Pulmonary Arterial Hypertension (PAH).
Date: February 9, 2016
Time: 8:30-9:00 am ET
Location: New York, NY
A live audio webcast and archive of the presentation will be available through the Events and Presentations page of the company's corporate website (www.steadymed.com).
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed intends to file an NDA for Trevyent in Q3 2016 and will commercialize Trevyent in the U.S. SteadyMed has licensed certain rights to Cardiome Pharma Corp. for the development and commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
CONTACT: Marylyn Rigby Director, Investor Relations and Marketing 925-272-4999 [email protected]
